Compare NSAID

arrow Created with Sketch.
arrow Created with Sketch.
6 Products

reset all

At-a-Glance

Description

FDA

CE Mark

Active Ingredients

Application

Status

Strength

remove

close Created with Sketch.
  • Formulations offer combinations of the three primary classes of medications used around the time of ocular surgery
  • One bottle reduces the total number of drops needed with an easy-to-follow postoperative regimen
  • Combined, compounded formulations can be more affordable
  • LessDrops are dispensed from the practice which offers convenience and assures surgeons that the patient has the medications they need

Combined Corticosteroid, Antibiotic, and NSAID Compounded Formulations for Postoperative Management

No (compounded formulation)

No

Formulation dependent

Topical

Prescription

Formulation dependent

remove

close Created with Sketch.
  • Dropless formulations are available from Imprimis' 503B outsourcing facility
  • Formulations include:
    • Tri-Moxi (Triamcinolone acetonide and moxifloxacin hydrochloride)
    • Dex-Moxi (Dexamethasone and moxifloxacin hydrochloride)
    • Dex-Moxi-Ketor (Dexamethasone, moxifloxacin hydrochloride and ketorolac)
    • Moxifloxacin
    • Hyaluronidase
    • Lidocaine/Epinephrine in BSS (PF/SF)
    • Phenylephrine/Lidocaine (PF/SF)

Dropless formulations are compounded combinations of steroid, antibiotic, and NSAID intended for use as an intracameral injection at the time of cataract surgery to minimize or eliminate the need for postoperative drops.

No (compounded formulation)

No

Formulation dependent

Injectable

Prescription

Formulation dependent

remove

close Created with Sketch.
  • Mechanism of Action: After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. Nepafenac and amfenac are thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.
  • Dosage: One drop should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.

Ilevro (nepafenac ophthalmic suspension) 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery.

Yes

Not specified

Nepafenac

Topical

Prescription

0.3%

remove

close Created with Sketch.
  • Mechanism of Action: Bromfenac is a nonsteroidal anti-inflammatory drug that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
  • Dosage: Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days postsurgery

Prolensa (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Yes

Not specified

Bromfenac sodium sesquihydrate

Topical

Prescription

0.7%

remove

close Created with Sketch.
  • Mechanism of Action: The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
  • Dosage: Instill one drop of BromSite to the affected eye twice daily morning and evening) beginning 1 day prior to surgery, the day of surgery, and 14 days postsurgery.

BromSite (bromfenac ophthalmic solution) 0.075% is a nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

Yes

Not specified

Bromfenac sodium sesquihydrate

Topical

Prescription

0.76%

remove

close Created with Sketch.
  • Mechanism of Action: Ketorolac is a non-steroidal anti-inflammatory drug that inhibits both cyclooxygenase enzymes (COX-1 and COX-2), resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma. Ketorolac prevents surgically induced miosis by inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris. Phenylephrine is an α1-adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris, resulting in pupil dilation. (According to the package insert)
     

Omidria (phenylephrine and ketorolac injection) 1%/0.3% is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Yes

Not specified

Ketorolac/Phenylephrine

Added to irrigation solution

Prescription

1%/0.3%